SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001213900-22-050834
Filing Date
2022-08-24
Accepted
2022-08-24 17:15:28
Documents
16
Period of Report
2022-08-08
Items
Item 4.01: Changes in Registrant's Certifying Accountant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 1 TO FORM 8-K ea164862-8ka1_allarity.htm   iXBRL 8-K/A 29592
2 LETTER FROM MARCUM LLP TO THE SECURITIES AND EXCHANGE COMMISSION DATED AUGUST 23 ea164862ex16-1_allarity.htm EX-16.1 9168
3 GRAPHIC ex16-1_001.jpg GRAPHIC 16205
4 GRAPHIC ex16-1_002.jpg GRAPHIC 5831
5 GRAPHIC ex16-1_003.jpg GRAPHIC 5435
  Complete submission text file 0001213900-22-050834.txt   258417

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE allr-20220808.xsd EX-101.SCH 2959
7 XBRL LABEL FILE allr-20220808_lab.xml EX-101.LAB 34240
8 XBRL PRESENTATION FILE allr-20220808_pre.xml EX-101.PRE 22359
10 EXTRACTED XBRL INSTANCE DOCUMENT ea164862-8ka1_allarity_htm.xml XML 4862
Mailing Address 210 BROADWAY SUITE 201 CAMBRIDGE MA 02139
Business Address 210 BROADWAY SUITE 201 CAMBRIDGE MA 02139 401-426-4664
Allarity Therapeutics, Inc. (Filer) CIK: 0001860657 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-41160 | Film No.: 221192304
SIC: 2834 Pharmaceutical Preparations